Latest Conference Articles

March 13th 2016, 8:00am

PER® Miami Breast Cancer Conference

There is a subset of low-risk patients with ductal carcinoma in situ for whom surgery alone is optimal and the Oncotype DX DCIS Score is a useful assay for identifying these individuals.

March 13th 2016, 8:00am

PER® Miami Breast Cancer Conference

A number of crucial findings were presented over the course of 2015 that helped to characterize an ever-growing trend toward personalized medicine in the treatment of breast cancer.

March 13th 2016, 6:00am

PER® Miami Breast Cancer Conference

Pathologic complete response may still have a role in accelerated neoadjuvant approvals for select patients with early stage breast cancer, despite the fact that it remains an unproven surrogate endpoint.

March 12th 2016, 5:35pm

PER® Miami Breast Cancer Conference

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses recent advancements in the field of HER2-positive breast cancer.

March 12th 2016, 3:49pm

PER® Miami Breast Cancer Conference

Amy Robach, breast cancer survivor and Good Morning America news anchor, describes her diagnosis of a 2 cm tumor in her right breast that appeared isolated on ultrasound and other subsequent scans.

March 12th 2016, 1:25pm

PER® Miami Breast Cancer Conference

Breast cancer survivor and Good Morning America news anchor Amy Robach delivered a compelling keynote address at the 33rd Annual Miami Breast Cancer Conference®.

March 12th 2016, 12:41pm

PER® Miami Breast Cancer Conference

The combination of the alpha-specific PI3K inhibitor alpelisib (BYL719) and fulvestrant (Faslodex) demonstrated promising early efficacy and mild toxicity in heavily pretreated postmenopausal women with ER-positive metastatic breast cancer.

March 12th 2016, 8:55am

PER® Miami Breast Cancer Conference

Among patients with HR+/HER2- or triple-negative metastatic breast cancer, nab-paclitaxel (Abraxane) improved time to treatment discontinuation, time to next treatment, and had a favorable safety profile compared with paclitaxel.

March 11th 2016, 3:33pm

PER® Miami Breast Cancer Conference

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses a clinical trial examining nelipepimut-S plus GM-CSF vaccine therapy as a treatment for patients with breast cancer.

March 11th 2016, 3:06pm

PER® Miami Breast Cancer Conference

The rapid advance of oncology drug development requires evolving beyond using overall survival in randomized trials as the only acceptable endpoint.

March 11th 2016, 2:27pm

PER® Miami Breast Cancer Conference

There is no clearly acceptable answer to the question of what is the appropriate margin for ductal carcinoma in situ.

March 11th 2016, 8:31am

PER® Miami Breast Cancer Conference

Carboplatin shows promise in treating metastatic BRCA-mutated triple negative breast cancer.

March 11th 2016, 6:46am

PER® Miami Breast Cancer Conference

William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.

March 10th 2016, 3:53pm

PER® Miami Breast Cancer Conference

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses using the word "cure" in patients with breast cancer who have not had recurrences of disease.

March 9th 2016, 8:59am

Multidisciplinary Head and Neck Cancer Symposium

Jonathan D. Schoenfeld, MD, MPH, physician, assistant professor of Radiation Oncology, Harvard Medical School, Dana Farber Cancer Center on the immunologic effects of chemotherapy and radiation in head and neck cancer.

March 9th 2016, 7:36am

Multidisciplinary Head and Neck Cancer Symposium

Ezra Cohen, MD, Associate Director, Professor of Medicine Moores Cancer Center, UC San Diego, discusses if lenvatinib should be used in the frontline or second-line setting in differentiated thyroid cancer.

March 8th 2016, 3:28pm

Multidisciplinary Head and Neck Cancer Symposium

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

March 4th 2016, 7:11am

Community Oncology Conference

The 2016 Community Oncology Conference, Innovation in Cancer Care: Moving From Theory to Practice, from April 13-15, will feature an expanded lineup of clinical presentations.

March 1st 2016, 2:34pm

Multidisciplinary Head and Neck Cancer Symposium

Randal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.

February 26th 2016, 12:45pm

Multidisciplinary Head and Neck Cancer Symposium

Jessica Frakes, MD, assistant professor of Radiation Oncology, Department of Radiation Oncology, Moffitt Cancer Center, discusses management of toxicities associated with treatment of patients with HPV-positive oropharyngeal squamous cell carcinoma.